[NCI CIRB] S1800A - A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care For Patients Previously Treated With Immunotherapy For Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study)
The purpose of this study is to compare any good and bad effects of using the study drugs ramucirumab with pembrolizumab compared to the usual approach alone in participants with previously treated for Non-Small Cell Lung Cancer.
non-small cell lung cancer
- Participants must have stage IV or recurrent non-small cell lung cancer
- Participants must not have certain genetic mutations unless they have progressed on usual care therapy
- Participants must have received exactly one line of anti-PD-1 or anti-PDL1 therapy for at least 84 days and must have progressed during or after treatment
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participants will be on study for up to 3 years from the time of study entry through follow up.
Knight Information Line - firstname.lastname@example.org or 503-494-1080